Used to treat depression and anxiety
Zydus Lifesciences has received final approval for Doxepin Hydrochloride Capsules USP, 150 mg (USRLD: Sinequan Capsules) from the United States Food and Drug Administration (USFDA).
Doxepin Hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety. It helps improve moods and feelings of well-being, relieves anxiety and tension, helps sleep better and increases the energy level.
The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).
Doxepin Hydrochloride Capsules USP, 150 mg had annual sales of USD 2.11 mn in the United States (IQVIA MAT Jan. 2023).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content